Pfizer Inc vs Vanguard Global ex-US Real Estate Index Fd ETF — how do they compare? Pfizer Inc trades at $27.88 (market cap $158.39B), while Vanguard Global ex-US Real Estate Index Fd ETF trades at $44.53. The key difference: Pfizer Inc pays a 6.19% dividend while Vanguard Global ex-US Real Estate Index Fd ETF pays none, and Pfizer Inc is trading nearer its 52-week high, Vanguard Global ex-US Real Estate Index Fd ETF nearer its low. Which is the better fit depends on your goals.
| PFE | VNQI | |
|---|---|---|
Market Cap | $158.39B | — |
Volume | 29,869,932 | — |
Sector | Health | — |
52-Week High | $29.02 | $50.76 |
52-Week Low | $23.60 | $43.26 |
Enterprise Value | $209.89B | — |
Dividend Yield | 6.19% | — |
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.78, down 2.36% today, with a consensus price target of $28.33 suggesting modest upside. The stock shows mixed technical signals with bullish moving averages but neutral oscillators. Recent earnings have consistently beaten expectations, though revenue declined from pandemic peaks. The company maintains strong cash flow generation and a solid dividend yield of approximately 3.1%.
Pfizer presents a value opportunity with reasonable valuation metrics and dividend stability, but faces headwinds from post-COVID revenue normalization and patent expirations. The company's pipeline progress in obesity and oncology could drive future growth, though execution risks remain. Analyst sentiment leans cautious with 59% hold ratings.
VNQI (Vanguard Global ex-U.S. Real Estate ETF) trades at $44.95, down 0.71% with a bearish technical signal. The ETF focuses on international real estate across 30+ countries, offering a higher dividend yield than domestic peers but showing lower recent returns. Moving averages indicate selling pressure while oscillators remain neutral. Recent news highlights institutional selling and comparisons with competing real estate ETFs.
The outlook remains cautious due to technical weakness and international real estate market volatility. Investment opportunity lies in global diversification and attractive dividend yield, but risks include currency exposure and underperformance versus U.S. real estate. The bearish technical setup suggests near-term pressure despite neutral fundamental positioning.
Trailing returns across standard periods
Latest headlines on both assets
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →